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Conclusions. The impact of FSGS on graft survival in chil-Loss of living donor renal allograft survival advantage in chil-
dren is greatest in LD transplants, resulting in loss of expecteddren with focal segmental glomerulosclerosis.
LD graft survival advantage. The rationale for LD grafts inBackground. Because of concerns of increased risk of graft
children with FSGS should be based on factors other thanloss with recurrent disease, living donor (LD) transplantation
better outcomes typically associated with LD transplantation.in children with focal segmental glomerulosclerosis (FSGS) has
been controversial.
Methods. The North American Pediatric Renal Transplant
Cooperative Study (NAPRTCS) database from January 1987 Among the acquired glomerulopathies, focal segmen-to January 2000 was examined to determine differences in demo-
tal glomerulosclerosis (FSGS) is the most common causegraphics, treatment, and outcomes in children with FSGS com-
of end-stage renal disease in children. Since the firstpared with other renal diseases.
Results. Data on 6484 children, 752 (11.6%) with FSGS, report 30 years ago, recurrence of FSGS has clearly been
demonstrated that FSGS patients were more likely to be older demonstrated as an important cause of graft loss in chil-
and black, and were less likely to receive either pre-emptive dren [1, 2]. In 1992, the North American Pediatric Renalor LD transplant (P , 0.001). No differences existed in human
Transplant Cooperative Study (NAPRTCS) Speciallymphocyte antigen (HLA) matching or immunosuppression
Study of recurrent FSGS demonstrated a recurrence rateregimens. Acute tubular necrosis occurred in more FSGS pa-
tients following LD (11.8 vs. 4.6%) or cadaveric (CD; 27.9 vs. of 20% after transplantation [3]. In addition, a special
16.3%) transplants (P , 0.001). Graft survival was worse for analysis based on original disease noted that children
LD FSGS patients (5 years 69%) compared with no FSGS
with FSGS as a primary diagnosis have reduced overall(82%, P , 0.001) and was not significantly different than CD
graft survival compared with other primary diagnosesgraft survival in the FSGS (60%) and No FSGS groups (67%).
The LD to CD ratios of relative risk of graft failure were higher in both living donor (LD) and cadaveric donor (CD)
in FSGS patients (test for interaction, P 5 0.01). Recurrence transplants [4]. This has been further confirmed by the
of original disease was the only cause of graft failure that latest annual report of the NAPRTCS [5].
differed between groups (P , 0.001). A greater percentage of
The lack of clear risk factors for disease recurrence,LD FSGS graft failures was attributed to recurrence (P 5 0.06).
unpredictable outcomes with current available therapies
for recurrent disease, and the overall decreased graft
1 The North American Pediatric Renal Transplant Cooperative Study survival have led many centers to suggest avoiding LD
(NAPRTCS) is supported by unrestricted educational grants from
transplantation in children with FSGS [2, 6, 7]. Such sug-Novartis, AMGEN, and Genentech. This work was presented in ab-
stract form at the American Society of Transplantation in May 1999. gestions to avoid LD transplants in children with FSGS
The NAPRTCS is a voluntary collaborative effort comprising over have been mainly based on anecdotal experience and
130 pediatric renal disease treatment centers in the United States,
have not been grounded by any retrospective or prospec-Canada, Mexico, and Costa Rica. Participating NAPRTCS centers are
listed in the NAPRTCS annual report (Feld et al, Pediatr Transplant tive review of a large patient population. For example,
1:146–162, 1997). several studies have demonstrated no correlation between
human lymphocyte antigen (HLA) matching and risk ofKey words: focal segmental glomerulosclerosis, recurrent renal disease,
kidney transplantation, acute tubular necrosis. recurrence [3, 6, 8]. In addition, there is no difference
in recurrence of FSGS between LD and CD grafts. Fur-Received for publication April 7, 2000
thermore, LD graft survival has exceeded CD graft sur-and in revised form July 10, 2000
Accepted for publication July 13, 2000 vival [3, 5]. However, we have recently noted in the
NAPRTCS database that whereas LD transplants areÓ 2001 by the International Society of Nephrology
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Table 1. Baseline characteristics of patients with focal segmentalperformed in 56% of Caucasian children without FSGS,
glomerulosclerosis (FSGS) and no FSGS
only 48% of Caucasian children with FSGS received LD
No FSGS FSGStransplants. We therefore undertook the present study
N 5 5732 N 5 752
to determine the correlation between FSGS and its re-
Sexcurrence in LD and CD renal transplant recipients. % Male 59.9 58.6
In this study, the NAPRTCS has sought to determine Raceb
White 64.1 49.7how children with FSGS differ from children with other
Black 14.0 31.8
diagnoses receiving renal transplants in North America, Other 22.0 17.4
Donor sourcebexamining differences in patient demographics, treat-
% living donor 53.1 44.3ment regimens, and outcomes. Since there is a known
Native nephrectomya % 24.2 29.0
difference in outcome between LD and CD transplants, Ageb
0–1 6.2 0.3the donor source in children with FSGS was compared
2–5 15.8 10.7to determine whether there were excess graft losses in 6–12 33.7 37.9
children who received LD transplants. .12 44.4 51.1
Dialysis status at time of transplantb
None 26.3 12.0
Hemodialysis 25.8 32.3METHODS Peritoneal dialysis 39.9 48.2
Both 6.1 7.6The NAPRTCS was created in 1987 to register and
aP , 0.01, bP , 0.001follow children up to 21 years of age who received renal
transplants in the United States and Canada. Methods
and data collection have been described previously in
detail [5, 9]. NAPRTCS is comprised of a Clinical Coor- Transplant characteristics
dinating Center, a Data Coordinating Center, and 140 Focal segmental glomerulosclerosis children were less
participating centers caring for children with renal dis- likely to undergo pre-emptive transplantation. Preemp-
ease in the United States, Canada, Mexico, and Costa tive transplant was performed in 10.0% of index trans-
Rica. Data collected one month following transplant and plants in FSGS children versus 25.4% of children with
at six-month intervals included transplant characteristics, No FSGS (P , 0.001). Similarly, children with FSGS were
immunosuppression regimen, graft rejection episodes, also less likely to receive a LD transplant. LD transplants
hospitalization, graft failure, and patient death. were performed in 44.3% of FSGS children compared
Data analysis was performed using standard univariate with 53.1% of the No FSGS group (P , 0.001). There
were no statistically significant differences for HLA-A,and multivariate statistical methods. Kaplan–Meier esti-
-B, or -DR matching in LD transplants or for HLA-Amates of graft survival, acute rejection, and patient sur-
or -B matching for cadaver grafts. For HLA-DR in CDvival were constructed. Relative risks of graft failure were
transplants, 52.5% of non-FSGS versus 58.5% of FSGSderived from Cox proportional hazards regression mod-
transplant had at least one DR match (P , 0.03).els and were adjusted for various patient characteristics.
Post-transplant course
RESULTS Treatment regimens. There were no clinically significant
differences in the treatment regimens between the FSGSDemographics
and No FSGS groups. Specifically, there was no differ-From January 1987 to January 2000, 6484 children re-
ence in the use of antibody induction protocols utilizing
ceived 7120 renal transplants. Of these transplants, 6484
OKT3, ALG, or ATG. In addition, mean day 30 post-
transplants were index transplants and 636 were subse- transplant dosages of prednisone, azathioprine, and cyclo-
quent transplants. FSGS (nephrotic syndrome) was the sporine did not differ between the two groups. In the FSGS
primary diagnosis in 752 patients (11.6%). For this study, group, mean 30-day post-transplant dosages of predni-
the patients were grouped as FSGS or No FSGS. sone were 0.66 mg/kg/day in the LD transplants versus
As shown in Table 1, there was no significant gender 0.74 mg/kg/day in the CD transplants (P 5 0.01). There
difference between the FSGS and No FSGS groups. The were no differences in azathioprine and cyclosporine
race and age distributions were significantly different, dosages.
with FSGS children more likely to be black (P , 0.001)
Graft functionand greater than 12 years of age (P , 0.001). There was
a small difference in incidence of native nephrectomy Overall, children with FSGS had twice the rate of
between the two groups (P , 0.01) and usage of pretrans- acute tubular necrosis (ATN), as defined by the need
for dialysis during the first week after transplantation,plant dialysis between the two groups (P , 0.001).
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Fig. 1. Percentage of acute tubular necrosis (ATN) by diagnosis and
allograft source. Symbols are: ( ) focal segmental glomerulosclerosis
(FSGS); (j) no FSGS; ***P , 0.001.
compared with No FSGS children (21 vs. 10%, P ,
0.001). Since there are known differences in the rates of
Fig. 2. Percentage of acute rejection by diagnosis and allograft source.ATN between LD and CD transplants, differences in
ATN between LD and CD recipients in the FSGS and No
FSGS groups were then examined. As shown in Figure 1,
the rates of ATN were significantly higher in LD recipi-
ents with FSGS (11.8%) compared with those with No
FSGS (4.6%; P , 0.001). Likewise, CD recipients with
FSGS had a higher rate of ATN (27.9%) compared with
CD No FSGS recipients (16.3%; P , 0.001). Thus, re-
gardless of donor source, children with FSGS had an
increased rate of post-transplant ATN compared with
the No FSGS group children.
There was little difference in long-term graft function
in surviving grafts between the FSGS and No FSGS
groups as measured by creatinine clearance at five years.
The LD group had mean calculated creatinine clearance
(Schwartz formula) of 61 mL/min/1.73 m2 for the No
FSGS group versus 62 mL/min/1.73 m2 for FSGS trans-
plants, while the respective values were 67 and 66 mL/
min/1.73 m2 for CD transplants.
Acute rejection
Acute rejection distributions are shown in Figure 2.
Fig. 3. Percentage of graft survival by diagnosis and allograft source.After adjustment for donor source, age, induction anti-
body use, race, gender, HLA-B, and HLA-DR matching,
there were no statistically significant differences in inci- year graft survival was 67 6 1.1%, while CD FSGS graft
dence of acute rejection between the FSGS and No FSGS survival was 60 6 3.1%. Thus, LD graft survival was
groups. Among FSGS patients, there was a trend toward significantly worse for FSGS patients as compared with
higher rejection rates in CD patients (P 5 0.07). No FSGS patients (P , 0.001). There were, however,
no statistically significant differences in graft survival
Graft survival between the LD FSGS, CD FSGS, and CD No FSGS
In total, there were 1516 graft failures with a median groups. These data indicate that the differential survival
follow-up for patients with functioning grafts of 46 months. advantage normally seen for LD transplants is lost in
Graft survival distribution curves are shown in Figure 3. patients with FSGS.
For LD No FSGS patients, five-year graft survival was Table 2 presents the relative risk of graft failure in
82 6 0.9%. For LD FSGS patients, five-year graft sur- patients with FSGS and those with No FSGS depending
on donor source. The relative risk was adjusted for priorvival was 69 6 3.1%. For CD No FSGS patients, five-
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Table 2. Relative risk (RR) of graft failure by diagnosis Patient survival
and allograft source
Patient survival curves are displayed in Figure 5. There
Donor source FSGS RR LD to CD ratio was no difference in patient survival between the FSGS
LD No 1.0 and No FSGS groups during the follow-up period.
CD No 1.50 0.67
LD Yes 1.61
CD Yes 1.68 0.96
DISCUSSION
Abbreviations are: LD, living donor; CD, cadaveric donor; FSGS, focal seg-
mental glomerulosclerosis. A living donor transplant is associated with a signifi-
cant emotional involvement and the expectation that the
donated kidney will survive for a prolonged period. To
date, no clear information is available regarding the roletransplant, prior dialysis, black race, recipient age less
of recurrence in decreasing the graft survival of a LDthan two years, HLA matching, and year of transplant.
graft. The large NAPRTCS database with 752 patientsThe relative risk of graft failure was increased in FSGS
with FSGS as a primary diagnosis before undergoingpatients receiving either LD or CD transplants.
renal transplantation has enabled us to analyze this ques-The relative risk of graft failure was denoted as 1.0
tion critically. We compared differences in patient demo-for LD transplants without FSGS. There was a 50%
graphics, treatment regimens, and outcomes, focusing ongreater risk of graft failure in CD transplants without
analyzing the differences in transplant outcomes in LDFSGS (relative risk of 1.50). The relative risk of graft
versus CD transplants in the FSGS and No FSGS groups.failure was 1.61 in LD transplants with FSGS—61%
Acute tubular necrosis is defined by NAPRTCS as thegreater than LD transplants without FSGS—and 1.68 in
need for dialysis during the first week post-transplanta-CD transplants with FSGS.
tion. Overall, patients with FSGS had twice the rate ofNext, the LD to CD ratios of relative risk of graft loss
ATN compared with those with No FSGS (21 vs. 10%).were examined. As shown in Table 2, the LD to CD
When we examined the incidence of ATN in LD andratio was 0.67 in the No FSGS patients compared with
CD patients, we found a significantly increased incidencea ratio of 0.96 in FSGS patient. Thus, the impact of FSGS
of ATN in both LD and CD patients with FSGS com-is greatest in LD transplants (P 5 0.013).
pared with those with No FSGS. ATN occurred in almostThe causes of graft failure as a percentage of trans-
three times as many LD patients with FSGS (11.8%)plants with designated cause of failure were examined
compared with those without FSGS (4.6%), and almostin the FSGS and No FSGS groups (Table 3). FSGS and
twice as many CD patients with FSGS (27.9%) comparedNo FSGS groups had similar percentages of transplants
with those with No FSGS (16.3%).failing secondary to chronic rejection, acute rejection,
These rates of ATN in patients with FSGS are signifi-thrombosis, death with function, technical complications,
cantly increased compared with patients with No FSGSor other causes (renal artery stenosis, infection, malig-
in both LD and CD transplants. It is unlikely that patientsnancy, cyclosporine toxicity, infection, and noncompli-
with FSGS would have any significant difference in theance). Importantly, the only significant difference in
incidence of perfusion or ischemic injury as the cause ofcauses of graft failure was due to recurrence of primary
ATN compared with patients without FSGS. Previousdisease, 6.1% in the FSGS group compared with 0.7%
studies found no differences in pretransplant panel reac-in the No FSGS group (P , 0.001).
tivity in FSGS patients versus controls [10]. Our dataRecurrence in the No FSGS patients is an uncommon
demonstrated no significant differences in HLA match-cause of graft failure. As shown in Figure 4, for the
ing between the FSGS and no FSGS groups in eitherLD No FSGS transplants, there were 19 failures from
LD or CD transplants. This is consistent with severalrecurrence among 492 graft failures (3.9%) in 3044 trans-
previous reports demonstrating that HLA matching didplants. For CD No FSGS transplants, there were 23 re-
not predict recurrence of FSGS [3, 6, 8]. Previous studiescurrences among 797 graft failures (2.9%) in 2688 pa-
have noted an increase in ATN in FSGS patients withtients. This difference is not statistically significant.
recurrent disease compared with those without recur-Also shown in Figure 4, graft loss caused by recurrence
rence [10, 11]. Thus, we must hypothesize that a possiblein FSGS patients accounted for a significantly higher
cause of the increased rate of ATN in patients with FSGSpercentage of graft failures in LD versus CD transplant
is immediate fulminant recurrent FSGS. Severe ATNrecipients. For LD FSGS transplants, 24 of 90 graft fail-
has been reported to occur in the native kidneys of pa-ures (26.7%) in 333 transplants were due to recurrence
tients with FSGS, and it is well known that immediatewhereas in CD FSGS transplants, 22 of 138 graft failures
recurrence of FSGS is associated with acute renal failure(15.9%) in 419 transplants were secondary to recurrence
and oligoanuria [2, 6, 10–12]. Immediately following(P 5 0.06). Thus, the impact of graft loss due to recur-
transplantation, urine output and renal function may berence is substantially more pronounced in the LD than
CD recipients. excellent; however, the patient may subsequently de-
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Table 3. Graft failure distributions
No FSGS N 5 5732 FSGS N 5 752
N of failures Cause distribution N of failures Cause distribution
Causes of graft failure % transplant for graft failure % % transplant for graft failure %
Nonfunction/technical 56 (1) 4.3 8 (1.1) 3.5
Thrombosis 156 (2.7) 12.1 21 (2.8) 9.2
Acute rejection 202 (3.5) 15.7 34 (1.5) 14.9
Chronic rejection 420 (7.3) 32.6 63 (8.4) 27.6
Recurrence 42 (0.7) 3.3 46 (6.1) 20.2
Death with function 144 (2.5) 11.2 13 (1.7) 5.7
Other 218 (4.7) 20.8 43 (6.1) 18.9
Total 1289 (100) 100 228 (100) 100
Data are causes of graft failure as a percentage of transplants with designated cause of failure. Causes of graft failure differ significantly (P , 0.001) for transplants
in the no FSGS and FSGS patients, as does the distribution of causes among graft failures.
Fig. 4. Recurrence as a cause of graft failure by diagnosis and allograft
source. Symbols are: ( ) living donor; (j) cadaveric donor. ***P 5
0.06.
velop oligoanuria in the presence of immediate recurrent
FSGS with severe proteinuria. Thus, immediate fulmi-
nant recurrence of FSGS post-transplantation likely pre-
disposes to ATN and may explain the increased inci- Fig. 5. Patient survival by diagnosis.
dence of ATN in the patients with FSGS. Furthermore,
ATN, as a result of fulminant recurrent FSGS, may play
survival approached that of CD graft survival. Thesea role in decreased graft survival in patients with FSGS.
results clearly demonstrate that the survival advantageBased on a study of 51 patients with FSGS, it has been
normally seen for LD transplants is lost in those patientssuggested that there is an increased incidence of acute
with FSGS.rejection episodes in patients with FSGS [10]. However,
The relative risk of graft failure was increased in FSGSour larger study failed to demonstrate any difference in
patients receiving either LD or CD transplants. In addi-acute rejection rates in patients with FSGS compared
tion, when we compared the ratios of relative risk ofwith those with No FSGS.
graft loss among LD and CD recipients in both the FSGSDecreased graft survival has been demonstrated in
and No FSGS groups, we found that the LD to CD ratiospatients with FSGS compared with other primary diag-
were significantly higher in the FSGS patients.noses [4, 5]. In our previous analysis [3], which involved
Recurrence of original disease does not necessarily127 patients with FSGS, we observed that LD graft sur-
portend graft loss in other disorders such as membrano-vival was superior to CD graft survival. However, with
proliferative glomerulonephritis; however, FSGS recur-the current study based on a patient population six times
rence is associated with increased graft loss [9]. In thislarger, graft survival was significantly worse for LD pa-
study, recurrence of primary disease as a cause of grafttients with FSGS compared with LD patients with No
failure was the only significantly different cause of graftFSGS. No statistically significant differences in graft sur-
failure between the FSGS and No FSGS groups, with avival were noted when comparing the LD FSGS, CD
FSGS, and CD No FSGS patients. Thus, LD FSGS graft ninefold increased incidence of recurrent disease in the
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